Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC)

被引：0
|
作者：
Hoff, Camilla Oliveira
McGrail, Daniel
Heeke, Simon
de Sousa, Luana Guimaraes
Li, Kaiyi
Bell, Diana
Mitani, Yoshitsugu
Marques-Piubelli, Mario L.
Cortez, Maria Angelica
Lin, Shiaw-Yih
Elamin, Yasir Y.
El-Naggar, Adel K.
Ferrarotto, Renata
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Cleveland Clin, Cleveland, OH USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6096
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial
    Hoff, Camilla Oliveira
    McGrail, Daniel
    Mitani, Yoshitsugu
    Heeke, Simon
    Sousa, Luana
    Santos, Erison
    Siqueira, Juliana Mota
    Li, Kaiyi
    Bell, Diana
    Marques-Piubelli, Mario L.
    Lin, Shiaw-Yih
    El-Naggar, Adel K.
    Ferrarotto, Renata
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] A phase 2 clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (ACC).
    Ferrarotto, Renata
    Bell, Diana
    Feng, Lei
    Li, Kaiyi
    Mott, Frank
    Blumenschein, George R.
    De Sousa, Luana Guimaraes
    Altan, Mehmet
    Marques-Piubelli, Mario L.
    Dal Lago, Eduardo Andreazza
    Kaya, Diana
    Godoy, Myrna
    Kupferman, Michael Elliot
    Glisson, Bonnie S.
    El-Naggar, Adel K.
    Elamin, Yasir Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma
    Ferrarotto, Renata
    Sousa, Luana G.
    Feng, Lei
    Mott, Frank
    Blumenschein, George
    Altan, Mehmet
    Bell, Diana
    Bonini, Flavia
    Li, Kaiyi
    Marques-Piubelli, Mario L.
    Dal Lago, Eduardo A.
    Johnson, Jason J.
    Mitani, Yoshitsugu
    Godoy, Myrna
    Lee, Anna
    Kupferman, Michael
    Hanna, Ehab
    Glisson, Bonnie S.
    Elamin, Yasir
    El-Naggar, Adel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2843 - +
  • [4] A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
    Tchekmedyian, Vatche
    Sherman, Eric Jeffrey
    Dunn, Lara
    Fetten, James Vincent
    Michel, Loren S.
    Kriplani, Anuja
    Morris, Luc
    Ostrovnaya, Irina
    Katabi, Nora
    Haque, Sofia
    Tran, Crystal
    Azar, Julian
    Pfister, David G.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Phase II study of axitinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma
    Ho, Alan Loh
    Sherman, Eric Jeffrey
    Fury, Matthew G.
    Baxi, Shrujal S.
    Haque, Sofia
    Sima, Camelia S.
    Antonescu, Cristina R.
    Katabi, Nora
    Pfister, David G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma (ACC).
    Dillon, Patrick Michael
    Petroni, Gina R.
    Moskaluk, Chris
    Fracasso, Paula M.
    Douvas, Michael G.
    Perez, Jose Ricardo
    Varhegyi, Nikole
    Zaja-Milatovic, Snjezana
    Thomas, Christopher Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Efficacy of cytotoxic chemotherapy in recurrent/metastatic adenoid cystic carcinoma (ACC)
    Wotman, Michael
    Hoff, Camilla Oliveira
    Bonini, Flavia
    Sawyer, Matthew
    Wang, Kaiwen
    Dal Lago, Eduardo Andreazza
    de Sousa, Luana Guimaraes
    Ferrarotto, Renata
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/ metastatic (R/M) adenoid cystic carcinoma (ACC)
    Hoff, C. O.
    de Sousa, L. G.
    Bonini, F.
    Dal Lago, E.
    Wang, K.
    Siqueira, J. Mota
    Cortez, M. A.
    Mitani, Y.
    Purushothaman, A.
    El-Naggar, A.
    Ferrarotto, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S577 - S578
  • [9] AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
    Ferrarotto, R.
    Bobbili, P.
    Bowles, D. W.
    Even, C.
    Gordon, G.
    Gutierrez, A.
    Metcalf, R.
    Muzaffar, J.
    Nguyen, C.
    Oliva, M.
    Perez, C. A.
    Rodriguez, C.
    Sendhil, S. R.
    Winquist, E.
    Wirth, L. J.
    Xia, B.
    Yovell, J.
    Ho, A. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S575 - S576
  • [10] A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
    Mohamadpour, Maliheh
    Sherman, Eric Jeffrey
    Kriplani, Anuja
    Fetten, James Vincent
    Dunn, Lara
    Michel, Loren S.
    Hung, Kin Wai
    Baxi, Shrujal S.
    McDonald, Erin
    Conybeare, Rachel
    Katabi, Nora
    Ostrovnaya, Irina
    Pfister, David G.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345